An Update on the Management of Relapsed and Primary Refractory Hodgkin's Disease

Research output: Contribution to journalArticle

16 Scopus citations


With the use of combined modality therapy for early stage disease and a risk-adapted approach for advanced stage disease, nearly 90% of patients with Hodgkin's lymphoma are cured with initial therapy. However, in patients who have primary refractory or relapsed disease, high-dose therapy and autologous stem cell transplantation is the best curative option. The use of peripheral blood progenitor cells has decreased transplant related mortality to less than 3%; but long-term progression-free survival as increased minimally. Although prognostic factors have been used to tailor therapy in de novo Hodgkin's lymphoma their utility in the relapsed-refractory setting has not been exploited. This update will discuss these important prognostic factors and try to guide oncologists in treatment decisions in this setting.

Original languageEnglish (US)
Pages (from-to)54-59
Number of pages6
JournalSeminars in Oncology
Issue number2 SUPPL. 4
StatePublished - Jan 1 2004
Externally publishedYes


ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this